LEO Pharma announces annual results 2022
Today, LEO Pharma released its financial results for 2022.
Financial highlights
- Revenue grew 7% vs. last year to 10,641 mDKK. The revenue growth in constant currency rates was 4% and in-line with guidance of 3-5%.
- Growth was driven by 8% growth in the Dermatology portfolio in constant currency rates. Growth was partly off-set by 4% decline in the Thrombosis business and reduced revenue from contract manufacturing of divested products.
- Since 2020 there has been a steady, organic acceleration of the Dermatology growth from 0% in 2020 to 4% in 2021 to 8% in 2022 in constant currency rates. The 8% growth in the Dermatology portfolio was mainly driven by the launch of AdbryTM in the U.S. and continued launch of Adtralza® in EU. In addition, we see solid growth for the established portfolio.
- Adjusted EBITDA loss was 1,253 mDKK, which represents an improvement of 478 mDKK vs. last year because of the revenue growth and lower costs driven by the transformation and restructuring program executed during 2021 and 2022.
- EBIT for 2022 amounted to a loss of 3,311 mDKK and is in line with the guidance of an operating loss (EBIT) of 3.1-3.3 bDKK.
CEO of LEO Pharma, Christophe Bourdon comments:
"We are progressing on our financial turnaround. 2022 was a year characterized by growth in our dermatology portfolio across markets and progress in our pipeline. In 2023, we are laser-focused on delivering positive EBITDA. I would like to thank all my colleagues for getting us to this turning point for the company."
Executing on growth strategy
In 2022, LEO Pharma continued its transformation, preparing to become more profitable and delivering positive EBITDA in 2023. A new commercial model was introduced at the start of the year with the purpose to simplify market operations and ensure full focus on the launch of Adtralza®/Adbry™ across markets. By the end of the year, the treatment was available to patients in 13 markets, including major markets such as the U.S., Spain, Germany, UK and France.
Strengthening the Global Leadership Team
In April, Christophe Bourdon took the reins as CEO. Brian Hilberdink joined as EVP Region North America, Sven Hauptmann as EVP Technical Development and Supply and Philip Eickhoff as CFO and EVP Global Finance and Business Services. The Global Leadership Team now has significant international industry competencies, setting LEO Pharma up to achieve the ambitions of growth and executing on a financial turnaround.
Advancements in R&D pipeline
LEO Pharma’s R&D pipeline progressed significantly in 2022 and achieved important milestones to support future growth. These include:
- Approval of Adtralza® in Japan
- Positive Phase 3 data for DELTA1 trial for delgocitinib, a topical pan-JAK inhibitor for treatment of chronic hand eczema, meeting primary and all key secondary endpoints.
- Positive Phase 2 data for Anti IL-22R, an anti-inflammatory monoclonal antibody for atopic dermatitis, progressing to Phase 2B.
These assets are all outcomes of strategic partnerships. This underpins the recent adjustment of the R&D strategy to have an increased emphasis on external innovation and partnerships.
On track towards sustainability targets
Progress was made towards the targets set out in the sustainability strategy.
The targets to reduce our carbon emissions from own operations by more than 50% from 2019 to 2030 and to ensure that 75% of our suppliers by emissions have set science-based targets by 2026, were validated by the Science Based Target initiative.
Outlook 2023
In 2023, LEO Pharma will continue its focus on delivering positive EBITDA, which is a first and necessary step to driving profitable and sustained growth towards 2025 and beyond. To deliver on the expectations, we anticipate revenue growth of 6-10% in 2023, driven by increasing sale of Adtralza®/Adbry™and growth in the strategic brands. We expect to deliver a low single-digit positive EBITDA margin. Taking the ordinary depreciation and amortization into account, this is expected to result in an operating loss (EBIT) in 2023.
Key figures
DKK million |
2022 |
2021 |
Delta |
Revenue |
10,641 |
9,967 |
7% |
Adjusted EBITDA |
(1,253) |
(1,731) |
28% |
EBITDA |
(1,574) |
(1,957) |
20% |
Operating profit (EBIT) |
(3,311) |
(4,156) |
20% |
Net profit |
(4,110) |
(4,868) |
16% |
|
Annual Report 2022
The full results are available in the LEO Pharma Annual Report 2022 on the company’s website at: www.leo-pharma.com
Changes to LEO Pharma’s Board of Directors
At LEO Pharma’s Annual General Meeting 2023 Jesper Mailind stepped down as Vice Chair of the Board of Directors, while continuing as Board member. Board member Paul Navarre was elected new Vice Chair.
- ENDS -
Contacts
Media contact:
Henrik Heskjær
hdtdk@leo-pharma.com
+45 3140 6180
About LEO Pharma
About LEO Pharma
LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 4,700 people, serving millions of patients across the world. In 2022, the company generated net sales of DKK 10.6 billion.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma Initiates Phase 2a DELTA NEXT Trial of Delgocitinib Cream in Adults with Mild to Severe Palmoplantar Pustulosis (PPP)3.6.2025 09:00:00 CEST | Pressemeddelelse
The phase 2a proof-of-concept trial will recruit up to 135 adult patients with mild to severe PPP to investigate the efficacy and safety of delgocitinib cream compared to cream vehicle. Delgocitinib cream has been shown to inhibit the activity of all four JAKs,(1,2) making it a potential therapeutic candidate for treating PPP.
LEO Pharma continues to strengthen strategic leadership in medical dermatology with appointment of Helle Hedegaard Juhl as new EVP of Global People & Corporate Affairs2.6.2025 10:00:00 CEST | Pressemeddelelse
A few weeks ago, LEO Pharma announced the appointment of a new EVP for Global People & Corporate Affairs (GPCA) – Helle Hedegaard Juhl will be joining LEO Pharma on July 1. She joins LEO Pharma, alongside recently appointed EVP for International Operations Frederik Kier, to strengthen the company’s leadership and support the next phase of LEO Pharma's strategic journey and transformation
LEO Pharma delivers 9% revenue growth at constant exchange rates and doubles adjusted EBITDA margin to 16%15.5.2025 09:00:00 CEST | Pressemeddelelse
Three-month interim report (Q1) 2025 (Unaudited)
To sharpen focus on the global commercialization of strategic products and the external partnership model, LEO Pharma makes changes to leadership13.5.2025 13:00:00 CEST | Pressemeddelelse
Ballerup, Denmark, 13 May 2025 -- At LEO Pharma, we have made significant progress on our transformation journey. With our strategy on the right track, we have reached a point on our journey that requires a focus on the long term and the profiles required to shape our future. In light of this, we are announcing the following changes to our Executive Management team: We will split the current Product Strategy and International Operations into two functions, and with this EVP Becki Morison will be leaving LEO Pharma, effective end of June 2025. Frederik Kier has been appointed as EVP, International Operations and will start at LEO Pharma on June 1, 2025. Frederik joins LEO Pharma from a position as Senior Vice President, Global Obesity Unit at Novo Nordisk. Frederik’s long career at Novo Nordisk spans commercial roles, including international experience as SVP Region Northwest Europe, and SVP Region AAMEO (Africa, Asia, Middle East and Oceania). Lisa Elliott, currently Vice President, Gl
LEO Pharma announces Positive Topline Phase 2b Results for Temtokibart in Moderate-to-Severe Atopic Dermatitis9.5.2025 12:00:00 CEST | Pressemeddelelse
Temtokibart achieved positive results for the primary endpoint for the 3 highest doses in a phase 2b clinical trial in adults with moderate-to-severe atopic dermatitis (AD) Temtokibart – also called LEO 138559 – is an investigational IL-22RA1 antagonist
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom